CA-JUNIPER-NETWORKS
14.7.2021 09:02:09 CEST | Business Wire | Press release
Juniper Networks , (NYSE: JNPR) a leader in secure, AI-driven networks, announced today that CMC Networks, a global service provider offering market-leading networking solutions, is the first Juniper partner to offer a managed AI-driven SD-WAN solution in Africa. A dynamic and self-optimizing network will deliver a superior experience to CMC’s customers, allowing them to easily modify their services, add new locations and spin up and down network speeds. Time-to-market is significantly reduced, enabling CMC to provision services faster.
By leveraging Juniper’s unique Session Smart® Router technology driven by Mist AI, CMC is delivering a unique tunnelless solution that is designed for scale and agility, coupled with automated provisioning, management and troubleshooting for maximum uptime, superior performance of real-time traffic and lower operating costs in both rural and urban environments.
News highlights:
- CMC chose the Session Smart Router and standardized on Juniper’s STEP (Service and Topology Exchange Protocol) in order to navigate network traffic with real-time data information. This allows accurate and immediate decision making autonomously, minimizing delays to ensure that network traffic arrives at its destination in the most efficient way possible. This helps to ensure that CMC’s customers receive a SD-WAN service that is high-performing, secure and reliable.
- The Juniper solution includes Secure Vector Routing (SVR), a transformational new intelligent routing architecture that enables CMC’s network to differentiate the way it delivers applications and services to end users. The SVR allows a network to identify problems and automatically decide the most effective path to re-route traffic. This supports business applications without user intervention, in support of the best possible user experience.
- The Juniper® Session Smart Router (SSR) fuels an advanced, service-centric networking solution and Mist AI engine that takes software-defined routing and SD-WAN to a new level. The SSR enables agile, secure, and resilient WAN connectivity. With tunnelless SSR technology, each session is secured with zero trust access by default, providing the highest level of security. Additionally, eliminating tunnel overhead increases bandwidth capacity and enables an improved user experience.
- CMC has been rolling out Session Smart Routers in Africa for the last three years, leveraging the organization’s scale and footprint to enable digital transformation across the region. In the future, the company plans to broaden its footprint into additional regions and deliver even more AI-driven managed services powered by Juniper, including wireless access.
- CMC is in the process of planning the rollout of additional cloud-hosted services driven by Mist AI, including WAN Assurance and the Marvis™ Virtual Network Assistant . These further streamline the deployment, operations and troubleshooting of its AI-driven SD-WAN environment with zero touch provisioning, customizable service levels, self-driving operations and AI-driven support to proactively address problems before customers even know they exist.
Supporting Quotes:
“SD-WAN is not a new technology and every SD-WAN player gives customers speed and power on the network. However, digital transformation strategies require a high level of intelligence, support and the ability to underpin business-critical applications - attributes that many SD-WAN vendors can’t provide. Juniper’s AI-driven SD-WAN gives CMC a level of intelligence and operational insight that we haven’t seen before.”
Geoff Dornan, Chief Technology Officer, CMC Networks
"Juniper’s AI-driven SD-WAN solution, powered by our Session Smart Router and Mist AI, enables us to be laser-focused on optimizing user experience. We recognized early that networks must be application-aware to support the demands of the evolving enterprise and to deliver the highest levels of user experience. Juniper ticks all the necessary boxes by delivering on the promise of a truly intelligent network that adapts as user requirements change. Juniper is thrilled that our innovative work with CMC has yielded this much-needed solution to enable consistent and excellent user experiences, even in the most challenging geographies, and we look forward to continued collaboration."
Sue Graham Johnston, Vice President and General Manager, Juniper Networks
Additional Resources:
CMC Networks: Connecting African & Middle Eastern Communities with Secure, Reliable SD-WAN (video)
About Juniper Networks
Juniper Networks is dedicated to dramatically simplifying network operations and driving superior experiences for end users. Our solutions deliver industry-leading insight, automation, security and AI to drive real business results. We believe that powering connections will bring us closer together while empowering us all to solve the world’s greatest challenges of well-being, sustainability and equality. Additional information can be found at Juniper Networks (www.juniper.net ) or connect with Juniper on Twitter , LinkedIn and Facebook .
Juniper Networks, the Juniper Networks logo, Juniper, Junos, and other trademarks listed here are registered trademarks of Juniper Networks, Inc. and/or its affiliates in the United States and other countries. Other names may be trademarks of their respective owners.
Category-Service Provider
View source version on businesswire.com: https://www.businesswire.com/news/home/20210714005023/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release
Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
